Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
103.00
+1.00 (0.98%)
Jul 30, 2026, 1:30 PM CST

TPE:6919 Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-284.11-351.92-588.83-488.46-286.16-224.29
Depreciation & Amortization
31.1730.6629.5127.8725.3423.28
Loss (Gain) From Sale of Assets
----0.11-
Stock-Based Compensation
171.49122.165.0522.9819.7174.76
Other Operating Activities
-265.83-187.28-6.69-0.35-0.36-3.27
Change in Accounts Receivable
0-1.312.71-4.77-3.12-
Change in Inventory
3.58-0.02-1.841.78-2.762.48
Change in Accounts Payable
-1.510.29-0.73-0.832.21-0.41
Change in Unearned Revenue
3.12-2.542.59-3.474.5-
Change in Other Net Operating Assets
11.59-35.88-24.0821.32-2.2216.77
Operating Cash Flow
-330.5-425.9-522.31-423.94-242.76-110.7
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-17.51-16.53-10-8.6-14.16-14.9
Sale of Property, Plant & Equipment
----0-
Sale (Purchase) of Intangibles
-1.27-0.61-1.09-1.09--
Investment in Securities
-6,394-5,603-2,478166.78-456.18-
Other Investing Activities
-17.33-4.61-0.01-0.2-
Investing Cash Flow
-6,430-5,624-2,489157.09-470.54-14.9

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Repaid
--8.88-8.58-8.22-12.6-93.98
Total Debt Repaid
-8.92-8.88-8.58-8.22-12.6-93.98
Net Debt Issued (Repaid)
-8.92-8.88-8.58-8.22-12.6-93.98
Issuance of Common Stock
88.6644.296,4993,042784.32720.88
Repurchase of Common Stock
-154.52-154.52----0.09
Financing Cash Flow
-74.78-119.116,4913,034771.72626.81

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
76.752.24-0.110.321.730.14
Net Cash Flow
-6,758-6,1173,4792,76760.15501.35

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-348.01-442.43-532.31-432.54-256.93-125.6
Free Cash Flow Growth
------
Free Cash Flow Margin
-914.89%-1163.16%-1197.97%-1111.01%-2004.12%-1017.90%
Free Cash Flow Per Share
-0.23-0.29-0.37-0.35-0.22-0.14
Levered Free Cash Flow
-323.46-401.63-391.26-266.4-171.06-74
Unlevered Free Cash Flow
-323.39-401.53-391.05-266.09-170.65-72.19

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
0.110.160.330.50.676.18
Cash Income Tax Paid
-----0.03
Change in Working Capital
16.78-39.46-21.3514.03-1.418.84